A Prospective Randomized Trial of Capecitabine Treatment in Patients With HNSCC
This prospective randomized controlled clinical Trial will be performed in patients with locally advanced squamous cell carcinoma of the head and neck. The objectives of the trial are to compare the efficacy and safety of Capecitabine treatment with placebo as adjuvant therapy to patients who have received radiotherapy.
Head and Neck Neoplasms
DRUG: Capecitabine
PFS (progression free survival), PFS is calculated from the date of randomisation to the date of treatment failure or death from any cause, whichever is first., 3-year
Overall survival, Overall survival is calculated from the date of randomization to death from any cause., 3-year|Locoregional failure-free survival, Locoregional failure-free survival is calculated from the date of randomization to the first locoregional failure., 3-year|Distant failure-free survival, Distant failure-free survival is calculated from the date of randomization to the first remote failure., 3-year|QoL(quality of life), Changes in quality of life were assessed by EORTC C30; QLQ-H\&N35 (V1.0), 3-year
This prospective randomized controlled clinical Trial will be performed in patients with locally advanced squamous cell carcinoma of the head and neck. The objectives of the trial are to compare the efficacy and safety of Capecitabine treatment with placebo as adjuvant therapy to patients who have received radiotherapy.